The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They reported modest decreases in International Prostate Symptom Score (IPSS), with a mean change from baseline to 6 weeks of −2.8 with tadalafil 5 mg versus −1.2 with placebo (p < 0.003), and to 12 weeks of −3.8 with tadalafil 5/20 mg versus −1.7 with placebo (p < 0.001) (McVary et al 2007).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as McVary et al 2007
In the citing paper
“McVary and associates reported a multicentered, randomized, double-blind, placebo controlled study of 281 men with LUTS secondary to BPH who were randomly assigned to once-daily tadalafil 5 mg for 6 weeks, followed by dose escalation to 20 mg for 6 weeks, or 12 weeks of placebo.”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as McVary et al 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tadalafil pharmacokinetics in healthy subjects
Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02553.x · Cited by 284
Research works printed but not linked: 18
- Wei, 2005, Urologic diseases in America project: benign prostatic hyperplasia, J Urol, 173, 1256, 10.1097/01.ju.0000155709.37840.fe · DOI
- Rosen, 2003, Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7), Eur Urol, 44, 637, 10.1016/j.eururo.2003.08.015 · DOI · Paper page
- Carson, 2004, The efficacy and safety of tadalafil: an update, BJU Int, 93, 1276, 10.1111/j.1464-410X.2004.04819.x · DOI
- Francis, 2005, Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters, Front Biosci, 10, 2097, 10.2741/1684 · DOI
- Uckert, 2001, Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate, J Urol, 166, 2484, 10.1016/S0022-5347(05)65621-2 · DOI
- Guh, 1998, Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor, Mol Pharmacol, 53, 467, 10.1124/mol.53.3.467 · DOI
- Sairam, 2002, Sildenafil influences lower urinary tract symptoms, BJU Int, 90, 836, 10.1046/j.1464-410X.2002.03040.x · DOI · Paper page
- Hopps, 2003, Novel agents for sexual dysfunction, BJU Int, 92, 534, 10.1046/j.1464-410X.2003.04425.x · DOI
- Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5 · DOI · Paper page
- Barry, 1995, Measuring disease-specific health status in men with benign prostatic hyperplasia, Med Care, 33, AS145
- Rosen, 1997, The International Index of Erectile Function (I.I.E.F.): a multidimensional scale for the assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
- Roehrborn, 2001, Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial, Urology, 58, 953, 10.1016/S0090-4295(01)01448-0 · DOI
- Barry, 2001, Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia, Urology, 58, 25, 10.1016/S0090-4295(01)01300-0 · DOI
- McVary, 2006, Sildenafil improves erectile function and urinary symptoms in men with erectile dysfunction and concomitant lower urinary tract symptoms, J Urol, suppl., 175, 527, 10.1016/S0022-5347(18)33829-1 · DOI
- Barry, 1995, Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?, J Urol, 154, 1770, 10.1016/S0022-5347(01)66780-6 · DOI
- Pinggera, 2004, Increased perfusion in the prostate after administration of PDE-inhibitor sildenafil, J Urol, suppl., 171, 425, 10.1016/S0022-5347(18)38820-7 · DOI
- Yoshimura, 2001, Nitric oxide modulates Ca+2 channels in dorsal root ganglion neurons innervating rat urinary bladder, J Neurophysiol, 86, 304, 10.1152/jn.2001.86.1.304 · DOI
- McVary, 2005, Erectile dysfunction and lower urinary tract symptoms secondary to BPH, Eur Urol, 47, 838, 10.1016/j.eururo.2005.02.001 · DOI
Cited by
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Metadata
- Authors
- McVary, K. T., Roehrborn, C. G., Kaminetsky, J. C., Auerbach, S. M., Wachs, B., Young, J. M., Esler, A., Sides, G. D., & Denes, B. S.
- Affiliations
- Department of Urology, Northwestern University Medical School, Chicago, Illinois
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas
- University Urology Associates, New York, New York
- California Professional Research, Newport Beach
- Atlantic Urology Medical Group, Laguna Woods, California
- Long Beach and South Orange County Medical Research Center, Laguna Woods, California
- ICOS Corp., Bothell, Washington
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana
- Venue
- Journal of Urology
- Published
- 2007-04
- Volume
- 177
- Issue
- 4
- Pages
- 1401-1407
- ISSN
- 0022-5347
- 1527-3792
- Cited by
- 302
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
